当前位置:
X-MOL 学术
›
Hypertension
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Left Ventricular Hypertrophy in Women With a History of Preeclampsia.
Hypertension ( IF 6.9 ) Pub Date : 2024-11-14 , DOI: 10.1161/hypertensionaha.124.23497 Maria G Hauge,Peter Damm,Klaus F Kofoed,Emma Louise Ries Møller,Andrea G Lopez,Anne S Ersbøll,Marianne Johansen,Per E Sigvardsen,Michael H C Pham,Jens P Goetze,Andreas Fuchs,Jørgen T Kühl,Børge G Nordestgaard,Lars V Køber,Finn Gustafsson,Jesper J Linde
Hypertension ( IF 6.9 ) Pub Date : 2024-11-14 , DOI: 10.1161/hypertensionaha.124.23497 Maria G Hauge,Peter Damm,Klaus F Kofoed,Emma Louise Ries Møller,Andrea G Lopez,Anne S Ersbøll,Marianne Johansen,Per E Sigvardsen,Michael H C Pham,Jens P Goetze,Andreas Fuchs,Jørgen T Kühl,Børge G Nordestgaard,Lars V Køber,Finn Gustafsson,Jesper J Linde
BACKGROUND
As a hypertensive disorder of pregnancy, preeclampsia is associated with increased cardiovascular morbidity and mortality later in life. Since early signs of myocardial affection could indicate a higher risk of future cardiovascular disease manifestations, we investigated whether women with prior preeclampsia have a higher prevalence of left ventricular hypertrophy compared with women from the general population and to what extent chronic hypertension affects any potential difference.
METHODS
In a cohort study, women aged 40 to 55 years with prior preeclampsia were compared with age- and parity-matched women from the general population. They underwent a research cardiac computed tomography, and the primary outcome was left ventricular hypertrophy, defined as a left ventricular mass index >30 g/m2.7.
RESULTS
In 679 women with prior preeclampsia and 672 controls (median age, 47 years), we found a higher prevalence of left ventricular hypertrophy (14.0% versus 6.4%) in the preeclampsia group with an odds ratio of 1.62, 95% CI (1.07-2.46), P=0.024, median of 15 years (range, 0-28) after pregnancy, after adjustment for cardiovascular risk factors, including chronic hypertension. Left ventricular hypertrophy was more frequent among women with preeclampsia with (26.2% versus 15.6%) and without (5.5% versus 2.4%) chronic hypertension, and a mediation analysis showed that chronic hypertension explained 22% of the association between preeclampsia and left ventricular hypertrophy.
CONCLUSIONS
Women with prior preeclampsia had a 2-fold higher prevalence of left ventricular hypertrophy compared with women from the general population, and preeclampsia was independently associated with left ventricular hypertrophy, regardless of the presence of cardiovascular risk factors, including chronic hypertension.
REGISTRATION
URL: https://www.clinicalTrials.gov; Unique identifier: NCT03949829.
中文翻译:
有子痫前期病史的女性的左心室肥大。
背景 作为一种妊娠期高血压疾病,子痫前期与以后生活中心血管发病率和死亡率的增加有关。由于心肌疾病的早期迹象可能表明未来心血管疾病表现的风险更高,因此我们调查了与普通人群中的女性相比,既往子痫前期女性的左心室肥厚患病率是否更高,以及慢性高血压在多大程度上影响任何潜在差异。方法 在一项队列研究中,将 40 至 55 岁既往患有子痫前期的女性与普通人群中年龄和产次匹配的女性进行了比较。他们接受了研究性心脏计算机断层扫描,主要结果是左心室肥大,定义为左心室质量指数 >30 g/m2.7。结果 在 679 名既往患有子痫前期的女性和 672 名对照组 (中位年龄 47 岁) 中,我们发现子痫前期组左心室肥厚的患病率较高 (14.0% 对 6.4%),比值比为 1.62,95% CI (1.07-2.46),P = 0.024,中位 15 年 (范围,0-28) 在调整心血管危险因素(包括慢性高血压)后。左心室肥厚在患有子痫前期 (26.2% 对 15.6%) 和无 (5.5% 对 2.4%) 慢性高血压的女性中更常见,中介分析显示慢性高血压解释了子痫前期与左心室肥大之间 22% 的关联。 结论 与一般人群女性相比,既往子痫前期女性左心室肥厚的患病率高 2 倍,并且子痫前期与左心室肥厚独立相关,无论是否存在心血管危险因素,包括慢性高血压。注册网址:https://www.clinicalTrials.gov;唯一标识符:NCT03949829。
更新日期:2024-11-14
中文翻译:
有子痫前期病史的女性的左心室肥大。
背景 作为一种妊娠期高血压疾病,子痫前期与以后生活中心血管发病率和死亡率的增加有关。由于心肌疾病的早期迹象可能表明未来心血管疾病表现的风险更高,因此我们调查了与普通人群中的女性相比,既往子痫前期女性的左心室肥厚患病率是否更高,以及慢性高血压在多大程度上影响任何潜在差异。方法 在一项队列研究中,将 40 至 55 岁既往患有子痫前期的女性与普通人群中年龄和产次匹配的女性进行了比较。他们接受了研究性心脏计算机断层扫描,主要结果是左心室肥大,定义为左心室质量指数 >30 g/m2.7。结果 在 679 名既往患有子痫前期的女性和 672 名对照组 (中位年龄 47 岁) 中,我们发现子痫前期组左心室肥厚的患病率较高 (14.0% 对 6.4%),比值比为 1.62,95% CI (1.07-2.46),P = 0.024,中位 15 年 (范围,0-28) 在调整心血管危险因素(包括慢性高血压)后。左心室肥厚在患有子痫前期 (26.2% 对 15.6%) 和无 (5.5% 对 2.4%) 慢性高血压的女性中更常见,中介分析显示慢性高血压解释了子痫前期与左心室肥大之间 22% 的关联。 结论 与一般人群女性相比,既往子痫前期女性左心室肥厚的患病率高 2 倍,并且子痫前期与左心室肥厚独立相关,无论是否存在心血管危险因素,包括慢性高血压。注册网址:https://www.clinicalTrials.gov;唯一标识符:NCT03949829。